Forward-looking research in drug delivery and therapies filled the sessions at this year’s meeting of the Association for Research in Vision and Ophthalmology.
Techniques for performing corneal collagen crosslink (CXL) are being evaluated and adapted, and at the same time, new applications are being developed.
Femtosecond lasers differ in their indications, energy delivery parameters, and hardware features. Understanding the implications of these factors will enable an objective assessment of the available technology.
Small incision lenticule extraction (SMILE), which has not yet been approved for refractive correction in the United States, may be less accurate and produce more irregular astigmatism than LASIK or PRK because of the imprecision resulting from the two incisions needed to create the lenticule. In addition, the technique for potential enhancements needs improvement. However, the treatment is promising and may stand the test of time as the technology advances.
The back layer of the cornea is made up of endothelial cells that keep the cornea clear. All cataract surgery does some damage to these cells, although due to the number of extra cells available in most corneas this damage doesn’t cause any problems. However, occasionally, post-cataract surgery endothelial cells don’t function well enough to keep the cornea clear, which can commonly cause corneal oedema. Here, Prof. Feinbaum describes a new treatment modality that has been designed to reduce and in most cases stop the oedema in 24–48 hours.
Immunomodulatory therapy for ocular inflammatory disease can be potent and effective, but physicians should be patient while awaiting results—and watch carefully for complications.